Last reviewed · How we verify
JNJ-63623872 600 mg
At a glance
| Generic name | JNJ-63623872 600 mg |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Nausea
- Headache
- Vomiting
- Dyspepsia
- Fatigue
- Pyrexia
- Cough
- Insomnia
- Constipation
- Oral pain
- Oedema peripheral
Key clinical trials
- Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications (PHASE3)
- A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation (PHASE1)
- A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment (PHASE1)
- A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment (PHASE1)
- A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection (PHASE2)
- A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults (PHASE1)
- Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-63623872 600 mg CI brief — competitive landscape report
- JNJ-63623872 600 mg updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI